Summary of COVID-19 levilimab studies

1. Lomakin et al., The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

206 patient levilimab late treatment RCT: 70% lower ICU admission (p=0.08) and 65% greater improvement (p<0.0001).
RCT 206 severe COVID-19 patients not requiring mechanical ventilation, showing higher sustained clinical improvement and lower ICU admission with levilimab. There was no difference in mortality.
Sep 2021, Inflammation Research, https://link.springer.com/10.1007/s00011-021-01507-5, https://c19p.org/lomakin